EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination

Valentina Angerilli, Matilde Callegarin, Ilaria Govoni, Giuseppe De Lisi, Michele Paudice, Paola Fugazzola, Alessandro Vanoli, Paola Parente, Francesca Bergamo, Claudio Luchini, Angelo Paolo Dei Tos, Federica Grillo und 4 weitere

Gastric Cancer · 2025-07 · 28 (4) · 569-578

DOI: 10.1007/s10120-025-01609-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, online erschienen am 09.04.2025. Verfasst von Valentina Angerilli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, via Gabelli 61, 35121, Padua, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Stomach Neoplasms, Esophagogastric Junction, Peritoneal Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca, Dipartimento di Medicina, Università degli Studi di Padova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temporal and spatial molecular heterogeneity contributes to resistance to targeted and immune therapies in gastric and esophagogastric junction carcinoma (G/EGJ). This study evaluates differences in biomarker expression between primary G/EGJ and paired peritoneal metastases (PM).

Methods

We analyzed 74 cases of primary G/EGJ and paired PM using immunohistochemistry for HER2, PD-L1, Claudin18 (CLDN18), DNA mismatch repair (MMR) proteins, p53, E-cadherin, and in situ hybridization for EBER. Biomarker concordance between primary and metastatic tumors was assessed.

Results

Primary G/EGJ were predominantly poorly cohesive (45.9%) or mixed-type (37.8%). Regarding predictive biomarkers, low rates of HER2 overexpression (5.4%), MMR deficiency (4.1%), and EBER positivity (1.4%) were observed, while PD-L1 CPS ≥ 1 occurred in 79.7% of cases and CLDN18 positivity was observed in 31.1% of cases. Concordance was perfect for MMR and EBER, while PD-L1 showed the highest discordance (32.4%). HER2 had a low discordance rate (2.7%). CLDN18 exhibited good concordance (86.5%) and showed consistent positivity in PD-L1- and HER2-negative primary tumors (28.6%).

Conclusion

G/EGJ with PM show distinct molecular features and spatial heterogeneity, with MMR, EBER, and HER2 demonstrating strong concordance, while PD-L1 showed greater variability. As for novel biomarkers, CLDN18.2 shows substantial concordance between primary G/EGJ and PM and could be a promising target in HER2/PD-L1-negative G/EGJ with PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorStomach NeoplasmsEsophagogastric JunctionPeritoneal NeoplasmsEsophageal NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overPrognosisErb-b2 Receptor Tyrosine KinasesB7-H1 AntigenFollow-Up StudiesClaudins

Stichwörter der Autor:innen

BiomarkersGastroesophageal cancerHeterogeneityTargeted therapy

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesB7-H1 AntigenClaudinsCD274 protein, humanCLDN18 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, via Gabelli 61, 35121, Padua, Italy.
  • ULSS2 Marca Trevigiana, Treviso, Italy.
  • Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
  • IRCCS San Matteo Hospital, Pavia, Italy.
  • Anatomic Pathology Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.

ORCID-Profile: Matteo Fassan

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Dipartimento di Medicina, Università degli Studi di Padova
  • Università degli Studi di Padova

Zitieren

APA

Angerilli, V., Callegarin, M., Govoni, I., De Lisi, G., Paudice, M., Fugazzola, P., Vanoli, A., Parente, P., Bergamo, F., Luchini, C., Dei Tos, A. P., Grillo, F., Lonardi, S., Mastracci, L., Spolverato, G., & Fassan, M. (2025). Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination. Gastric Cancer, 28(4), 569-578. https://doi.org/10.1007/s10120-025-01609-7

Vancouver

Angerilli V, Callegarin M, Govoni I, De Lisi G, Paudice M, Fugazzola P, et al. Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination. Gastric Cancer. 2025;28(4):569-578. doi:10.1007/s10120-025-01609-7

BibTeX
@article{Angerilli2025,
  author = {Angerilli, Valentina and Callegarin, Matilde and Govoni, Ilaria and De Lisi, Giuseppe and Paudice, Michele and Fugazzola, Paola and Vanoli, Alessandro and Parente, Paola and Bergamo, Francesca and Luchini, Claudio and Dei Tos, Angelo Paolo and Grillo, Federica and Lonardi, Sara and Mastracci, Luca and Spolverato, Gaya and Fassan, Matteo},
  title = {Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination},
  journal = {Gastric Cancer},
  year = {2025},
  volume = {28},
  number = {4},
  pages = {569--578},
  doi = {10.1007/s10120-025-01609-7}
}
Kostenlos starten →